Pre-Test Addressing Unmet Needs in Ulcerative Colitis: Understanding the Utility of Newer and Emerging Targeted Therapies Pre-Test According to ACG guidelines, mild UC can be defined by which of the following? Continuous blood in stool and continuous urgency, calprotectin >150-200, Mayo endoscopic score 3 Frequent blood in stool and frequent urgency, calprotectin >150-200, Mayo endoscopic score 2 Intermittent presence of blood in stool and occasional urgency, calprotectin >150-200, Mayo endoscopic score 1 No presence of blood in stool and occasional urgency, calprotectin Unsure Which of the following best describes the mechanism of action of S1P receptor modulators to address the chronic inflammation associated with the pathogenesis of IBD? Decrease STAT protein phosphorylation Increases anti-inflammatory cytokines to promote gut healing Inhibits cytokine production by epithelial cells and immune cell activation Inhibits recruitment of lymphocytes and reduces the number in systemic circulation Unsure Which of the following is a selective S1P receptor modulator (engaging S1P receptors 1, 4, and 5) that demonstrated statistically significant improvements in clinical remission, endoscopic improvement, symptomatic remission, and mucosal healing among patients with moderate to severe UC at weeks 12 and 52? Amiselimod Etrasimod Fingolimod Siponimod Unsure How confident are you in your ability to optimally position S1P receptor modulators and JAK inhibitors in tailored UC treatment plans? Very confident Confident Somewhat confident Not very confident Not at all confident
